Introduction
Brain serotonin (5-hydroxytryptamine; 5-HT) is implicated in the control of cognitive and socioemotional abilities in various neuropsychiatric and neurological disorders (Kranz et al., 2010; Kiser et al., 2012; Olivier, 2015) . Among the subtypes of 5-HT receptors, the 5-HT 1A receptor is most widely distributed in the brain and is a therapeutic target for a variety of CNS disorders (Pazos and Palacios, 1985; Maurel et al., 2007; Celada et al., 2013; Billard et al., 2014 Recently, Lemoine et al. (2012) developed a 5-HT 1A receptor agonist PET probe by 18 F-labeling of F13714, a highly selective and efficacious 5-HT 1A receptor agonist with very high binding affinity (Ki values <0.1 nM) (Koek et al., 2001 ). F13714 exhibits high selectivity for 5-HT 1A receptor in more than 40 other binding sites, including receptors, transporters, ion channels, and enzymes, which were tested by in vitro binding screening assays using both native rat and recombinant human binding sites (Assié et al., 2006) and shows high sensitivity to endogenous agonist, 5-HT, and G-protein uncoupling by Gpp(NH)p in the rat brain (Lemoine et al., 2012) . Further, 18 F-F13714 rapidly penetrates the blood-brain barrier with high lipophilicity and is only slightly metabolized in vivo (Lemoine et al., 2012) . Intriguingly, a PET study using anesthetized cats indicated that 18 F-F13714 preferentially binds to cortical rather than hippocampal 5-HT 1A receptors, in contrast to findings with antagonist tracers showing a higher density in the hippocampus than in the cortex (Aznavour and Zimmer, 2007; Lemoine et al., 2012) . These data reinforce the interpretation that the capacity to label "functional" 5-HT 1A receptors may differ substantially between agonist and antagonist radiotracers. In addition, a variety of rat electrophysiological, neurochemical, and behavioral studies have indicated F13714 exhibits a biased agonist profile of activity at specific 5-HT 1A receptor subpopulations, notably in the raphe region and the striatum (Newman-Tancredi et al., 2009; Iderberg et al., 2015; van Goethem et al., 2015; de Boer and Newman-Tancredi, 2016) . A recent study in phMRI showed that F13714 and another biased agonist, F15599, induced specific pattern of changes in blood oxygen level dependent (BOLD) signal in a neuronal circuit in contrast to those induced by a classical agonist, 8-OH-DPAT, or a silent antagonist, MPPF, supporting the concept that biased agonists can preferentially target subpopulations of 5-HT 1A receptors in specific brain regions (Becker et al., 2016) . Investigation of brain imaging with 18 F-F13714 is therefore desirable to better understand agonist interactions at subpopulations of 5-HT 1A receptors.
Although previous experiments have demonstrated the utility of 18 F-F13714 as a PET probe for the 5-HT 1A receptor in cat (Assié et al., 2006; Maurel et al., 2007; Lemoine et al., 2012) , the brain labelling pattern of 18 F-F13714 in nonhuman primate has not been described. This would be highly informative, because the translatability of the novel biased agonist profile of F13714 to primate species (and particularly to human) remains to be established. Thus, use of nonhuman primates such as common marmosets, a species that shows human-like sociability involving serotoninergic neurotransmission (Yokoyama et al., 2013) , is an attractive option for preclinical PET studies. A supplementary issue that influences translatability of PET imaging data between animal and human studies is the use of anesthetics that may modify the binding profiles of target receptors (Elfving et al., 2003; Seeman and Kapur, 2003; Lancelot and Zimmer, 2010; Li et al., 2013) . Carrying out marmoset PET without anesthesia may therefore be useful for identifying potential confounds in PET imaging due to anesthesia and for mapping the function of serotonin in vivo (Yokoyama et al., 2010; Yokoyama and Onoe, 2015) .
The present study therefore had 2 aims. Firstly, to conduct PET scans in a cohort of marmosets using the agonist PET probe, 18 F-F13714, and compare this with a well-characterized 18 F-labeled antagonist PET probe, 18 F-MPPF. Secondly, experiments were performed under both consciousness and isoflurane-anesthesia conditions. This study unveiled a differential binding distribution between agonist and antagonist PET probes, with differential impacts of isoflurane. Thus, the agonist PET probe, 18 F-F13714, can provide functional binding profile of 5-HT 1A receptors in the primate brain, which will help to further our understanding of the function of serotoninergic system in the human brain and its role in cognitive and socioemotional abilities.
MATERIALS AND METHODS

Subjects
Four adult male common marmosets (Callithrix jacchus) (including one pair of siblings), at 3.5 to 4.0 years of age at the start of experiments, were used in these studies. Animals were housed in pairs in home cages measuring 600 × 430 × 650 mm under a 12-h-light/-dark cycle (light: 8:00 am to 8:00 pm). Each cage had 2 wooden perches, a food tray, and an automatic water dispenser. Animals were fed solid food (CMS-1, CLEA Japan, Inc., Tokyo, Japan) soaked in water and mixed with a suitable amount of powdered milk formula, honey, gluconic acid calcium, vitamin C, and lactobacillus probiotic twice a day, supplemented with chopped boiled eggs or bananas once a week. Each animal underwent PET scans 4 times with 18 F-F13714 and 18 F-MPPF within 1 year, both under consciousness and isoflurane anesthesia at a 3-week interval.
To perform PET scans on conscious marmosets without causing discomfort to the animals, experiments were conducted
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according to a previously published method (Yokoyama et al., 2010) . Briefly, animals were adequately trained for fixation on the chair with an acrylic head holder that was surgically attached to the skull surface before PET experiment. For PET scans under anesthesia, animals were maintained with isoflurane inhalation via a mask lying on a bed without the use of a head holder. MRI of the brain was acquired before surgery of the head holder attachment with a 3T MRI scanner (Magnetom Allegra, Siemens, Erlangen, Germany) under pentobarbital anesthetic for the anatomical alignment of PET data. Animals were maintained and handled in accordance with the recommendations of the United States National Institutes of Health, and all procedures were approved by the Animal Care and Use Committee of RIKEN Kobe Branch (MAH21-10).
PET Scans
PET scans in conscious marmosets were performed with a PET scanner (microPET Focus220; Siemens Medical Solutions, Knoxville, TN) as previously described (Yokoyama et al., 2010) . After cannulation via a tail vein, animals were fixed in a sitting position (tilted to 45°) in the scanner. For PET scans in anesthetized animals, inhalation induction with sevoflurane and then isoflurane anesthesia was maintained at 1% concentration, with monitoring of heart rate (150-200 beats/min) and peripheral oxygen saturation (>98%) with pulse oximetry (BSM-3592; Nihon Kohden, Tokyo, Japan). Animals were laid in the face-up position on a bed with the heads softly fixed by round ended ear bars and placed horizontally in the PET scanner. For both conscious and anesthetized animals, a transmission scan with a 68 Ga pin source was performed for 30 min before an emission scan.
We used 2 kinds of PET probes: 18 F-F13714 and 18 F-MPPF ( Figure 1 ). According to a previous method (Lemoine et al., 2012) , 18 F-F13714 was prepared by aromatic nucleophilic substitution reaction of the previously reported nitro precursor (3 mg, 6.7 µmol) with 18 F-KF/Kryptofix 2.2.2 in DMSO (200 μL).
18
F-Fluoride anion was produced by a cyclotron (HM-12S; Sumitomo Heavy Industry Ltd., Tokyo, Japan). The radiochemical purity and chemical purity were >99% and >93%, respectively. The specific activity was 67.7 ± 13.4 GBq/μmol at the end of synthesis. According to a previous method (Le Bars et al., 1998), 18 F-MPPF was prepared by aromatic nucleophilic substitution reaction of the previously reported nitro precursor (5 mg, 10.8 µmol) with 18 F-KF/Kryptofix 2.2.2 in DMSO (500 μL). The radiochemical purity and chemical purity were both >99%. The specific activity was 182.5 ± 65.6 GBq/μmol at the end of synthesis. In both tracers, PET scans were performed for 90 minutes immediately after bolus injection of radiolabeled tracers ( 18 F-F13714: 162.2 ± 21.4 MBq/kg; 18 F-MPPF: 158.6 ± 14.4 MBq/kg). Images were acquired with a 3-dimensional list-mode and reconstructed by a filtered back projection algorithm using a Hanning filter cutoff 0.5 cycles/pixels with the attenuation correction using blank and transmission images. A spatial resolution at the center of the field of view is approximately 1.35 mm in full width at halfmaximum. The dynamic histogram acquired during 90 minutes (6 × 10 seconds, 6 × 30 seconds, 11 × 60 seconds, 15 × 180 seconds, 3 × 600 seconds) was used for data analyses.
Data Analysis
Reconstructed images were processed with image analysis software PMOD (version 3.5, PMOD Technologies Ltd., Zurich, Switzerland). First, individual PET images were aligned on each individual MR image by rigid matching using PMOD's image registration and fusion tool (PFUS). Next, the template of the brain MR image that was previously prepared (Yokoyama et al., 2013) was used for normalization of individual PET images. PET images of the brain were deskulled according to the structural information from individual brain MR images. Individual brain MR images were then registered to the standard space of the template brain MR image by brain normalization. By using these registration matrices, PET images were transformed and normalized.
The normalized individual PET images were used to elucidate the quantitative 18 F-F13714 and 18 F-MPPF binding to 5-HT 1A receptors in the brain. We calculated binding potential (BP ND ) by quantifying the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in brain tissue using a nonlinear fitting method involving a simplified reference tissue model (SRTM), using cerebellum as a reference region and the cingulate cortex for Bars et al., 1998; Lemoine et al., 2012) , there is controversy as to whether the cerebellum is devoid of the 5HT 1A receptors in vivo Shrestha et al., 2012) . However, we have confirmed in this study that the time activity curves of 18 F-F13714 and 18 F-MPPF in the cerebellum show the lowest uptake among brain regions, and also that when the ROI of cerebellum is divided into the gray and white matter, the shape of these TACs are very similar to each other. Therefore, using cerebellum as a reference region should be meaningful in our PET study at present. The parametric images of BP ND were created by SRTM2 with fixing of k2' estimated by SRTM. Regional BP ND values were obtained by applying several anatomical regions of interest (ROIs) that were drawn manually in the template brain MR image with reference to the stereotaxic brain atlas of the common marmoset (Paxinos et al., 2011) (Figure 5 ) on the following regions: the frontal cortex, parietal cortex, temporal cortex, occipital cortex, cingulate cortex, at minimum in the raphe. The between-subject variability of BP ND in each region was assessed for both conditions as the CV as follows:
The within-subject variability across conditions was assessed for each region as follows:
The reliability of the measurement per region was evaluated by comparing the within-subject variability (WS) to the betweensubject variability (BS) in terms of intraclass correlation coefficient ICC (1, 1) as follows, where the MSS represents mean sum of squares and is calculated for the WS and the BS situation:
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Statistics
The effect of isoflurane on regional BP ND was analyzed separately by 2-way ANOVA (region × condition) for F-MPPF across ROIs used the Deming regression model, taking measurement errors for both parameters separately on conscious and anesthetic scans. Statistical analyses were performed using R2.8.1, and a P value of .05 was defined as the threshold of statistical significance.
RESULTS
PET Scans with
18
F-F13714
18 F-F13714 uptake in the marmoset brain was rapid and showed apparently quasi-irreversible kinetics over the observation period (Figure 2 ), suggesting very high affinity binding of this tracer to the 5-HT 1A receptor or, potentially, a rapid internalization of the receptors, although this remains speculative. In conscious animals, the distributed radioactivity indicated a distinctive pattern with a high level of uptake in the cingulate and insular cortices, raphe nucleus, thalamus, and tectum. Intermediate uptake was observed in the hippocampus, other cortical areas, amygdala, and hypothalamus, but also in the caudate and putamen. Low uptake was observed in the cerebellum (Figure 2a) .
In animals anesthetized with isoflurane, there were subtle changes in the shape of the time activity curves, with an initial rapid rise followed by a slight decrease before showing uptake levels and quasi-irreversible kinetics similar to those observed in conscious animals (Figure 2b ). There were differences in the uptake level in the various brain regions in anesthetized animals compared with conscious animals, with higher uptake in the hippocampus, amygdala, and hypothalamus and lower uptake in the caudate nucleus and putamen (see below for statistical information).
Variability was observed in 18 F-F13714 binding between individual animals in both conscious and anesthetic conditions (Table 1) . Regional BP ND values had a moderate variation across subjects in conscious animals (CV: 26.1-58.0%, average 38.4%), but a higher variability in anesthetized animals (CV: 17.4-103.6%, average 53.7%). Two-way ANOVA revealed that isoflurane did not significantly change overall 18 F-F13714 BP ND (F(1, 42) = 0.0013, P = .971), as the effects of anesthesia were region specific and not unidirectional. A significant interaction effect of region and condition was observed (F(13, 42) = 4.392, P = .0001). Tukey's posthoc comparison after Bonferroni correction showed that isoflurane significantly increased 18 F-F13714 BP ND in the hippocampus (t = 3.65, P < .01) and hypothalamus (t = 3.19, P < .05) and decreased in the putamen (t = 3.19, P < .05). The high ICC (0.37-0.95, average 0.73) indicated a good reliability of individual variations in regional 18 F-F13714 binding, even across conscious and anesthetic conditions.
PET Scans with 18
F-MPPF 18 F-MPPF uptake was similar in shape of the time activity curves between the conscious and anesthetic conditions, with a rapid rise and gradual decline, although the uptake level and variance was generally increased in anesthetized animals ( Figure 3) . A high level of uptake was observed in the hippocampus and amygdala; moderate uptake in the cingulate, insular, and frontal cortices, raphe nucleus, and tectum; lower uptake in the thalamus, striatum, hypothalamus, and other cortical areas; and low uptake in the cerebellum. There was some variation between individual animals in 18 F-MPPF regional BP ND values (although this was lower than that observed with 18 F-F13714): under conscious conditions, CV values were 9.4% to 48.4%, average 22.5%; under anesthetized conditions: CV values were 10.1% to 94.5%, average 36.5% (Table 2) . Two-way ANOVA revealed that isoflurane significantly increased Averaged BP ND images from all subjects for 18 F-F13714 and 18 F-MPPF are shown in Figure 5 . Notably, there was no correlation of BP ND between the 2 tracers in conscious animals (F(1,12) = 1.19, P = .30), while a significant correlation was observed under isoflurane anesthesia (F(1,12) = 8.92, P = .01) (Figure 6 ). These results suggest that the population of 5-HT 1A receptors identified by 18 F-F13714 was proportional to that identified by 18 F-MPPF under anesthesia conditions, but not when PET experiments were carried out in conscious marmosets.
Discussion
This is the first report on PET imaging of 18 F-F13714, a novel, selective 5-HT 1A receptor agonist PET probe, in nonhuman primate brain. The results indicate that it displays a highly distinctive brain distribution pattern in conscious and anesthetized common marmosets that differs markedly from that of a wellcharacterized antagonist PET probe, 18 F-MPPF. The overall brain distribution pattern of 18 F-F13714 binding in marmosets exhibited some consistency with previous reports of 5-HT 1A receptor densities in rats, baboons, rhesus monkeys, and humans determined with other PET probes, including 18 F-MPPF (Pike et al., 1996; Maeda et al., 2001; Costes et al., 2007; Milak et al., 2010 Milak et al., , 2011 Wooten et al., 2011) . Thus, higher binding of 18 F-F13714 was observed in regions classically associated with 5-HT 1A receptor expression, including the cortical regions, hippocampus, amygdala, hypothalamus, and raphe nucleus (Figures 4 and 5) . However, the intensity of the binding distribution in these brain regions was strikingly different from that seen with 18 F-MPPF. Indeed, 18 F-F13714 showed lower binding in the F-F15599 (Lemoine et al., 2010 (Lemoine et al., , 2012 . In contrast, the antagonist tracer, As discussed previously (Lemoine et al., 2012) , F13714 is highly selective for 5-HT 1A receptors, and its neurochemical and behavioral effects are blocked by a 5-HT 1A receptor antagonist (WAY100635) (Assié et al., 2006; Iderberg et al., 2015) . Accordingly, the in vitro autoradiographic labeling seen with 18 F-F13714 on rat brain sections was completely blocked by co-incubation with WAY-100635, and in vivo cat brain PET labelling was prevented by preinjection of WAY-100635 (Lemoine et al., 2012) . These considerations suggest that differences in labeling patterns between the 2 tracers may relate to the agonist properties of 18 F-F13714 that enable it to distinguish a 5-HT 1A receptor subpopulation of high-affinity sites (Assié et al., 2006; Maurel et al., 2007; Lemoine et al., 2012) , a concept described previously for the 5-HT 1A receptor in baboons with 11 C-CUMI-101 (agonist) and 11 C-WAY100635 (antagonist) (Kumar et al., 2012) . In the case of F13714, extensive evidence supports the notion that it acts as a biased agonist that preferentially targets 5-HT 1A receptors in specific brain regions, including the raphe, striatum, and thalamus (Assié et al., 2006; Iderberg et al., 2015; Becker et al., 2016) .
Thus, F13714 potently inhibits 5-HT release in cortex and striatum (Assié et al., 2006; Iderberg et al., 2015) , reverses L-DOPAinduced dyskinesia in Parkinsonian rats, and stimulates a BOLD signal in the raphe, striatum, and motor cortex (Becker et al., 2016) , results that are consistent with the present study showing accentuated binding to these brain regions in marmoset brain. Although the molecular basis for this remains to be clarified, it is likely due to a preferential interaction of 18 F-F13714 with 5-HT 1A receptors that are coupled to specific G-protein subtypes release in both hippocampus and striatum (Assié et al., 2006; Iderberg et al., 2015) , responses controlled by somatodendritic 5 HT 1A receptors. An ex vivo immediate early gene expression study showed that F13714 potently elicits increases in c-fos expression in dorsal and median raphe (Cussac et al., 2007) . Taken together, these observations suggest that 18 F-F13714 has an accentuated activity at presynaptic 5-HT 1A receptors. However, it should be noted that, although binding profile of F13714 has been extensively characterized in the rat, in the marmoset brain it is still under investigation. Some caution is therefore warranted until further studies of this issue have been carried out.
Some additional points should be noted. Firstly, although the agonistic profile of 18 F-F13714 has not been directly demonstrated in marmoset brain, it may be inferred by the distinctive binding kinetics we observed in anesthetized animals. Indeed, whereas isoflurane caused a global increase in 18 F-MPPF uptake throughout the brain (Figure 3) , binding kinetics of 18 F-F13714 showed region-specific changes. The binding in tectum and occipital cortex increased rapidly, peaked, and then decreased slightly before stabilizing. In contrast, binding in amygdala and frontal cortex did not show this temporal profile and resembled that observed in conscious marmosets (Figure 2 ). It is tempting to speculate that these different profiles may be caused by changes in endogenous serotonin levels, which, by competing for binding to 5-HT 1A receptors, could change the binding potential of 18 F-F13714. Indeed, isoflurane was reported to decrease extracellular 5-HT in the hippocampus and the frontal cortex (Whittington and Virág, 2006; Mukaida et al., 2007) and inhibit 5-HT neuron firing in the medullary raphe (Johansen et al., 2015) . It may therefore be surmised that, because its agonist activity, 18 F-F13714 may have a higher sensitivity than for 18 F-MPPF for measuring receptor occupancy by endogenous synaptic 5-HT release.
The assertion that agonist PET probes can identify a subset of 5-HT 1A receptors whereas antagonist tracers label the total receptor population (Aznavour et al., 2006; Lemoine et al., 2010; Kumar et al., 2012; Billard et al., 2014) is supported by the observation that 18 F-F13714 showed lower BP ND values than 18 F-MPPF in all brain regions. Linear regression of the binding potential values of 2 tracers in anesthetized marmosets achieved statistical significance (see Figure 6 and Results) and suggested that 5-HT 1A receptors labelled by 18 F-F13714 constitute about onethird of the total receptor population ( Figure 6 ). This implies a ratio of approximately 1:2 for G-protein-coupled receptors in a high-affinity state to those in a low-affinity state. This ratio is similar to that reported using 11 C-CUMI-101 and 11 C-WAY100635 in anesthetized baboons, although the agonist activity of 11 C-CUMI-101 may be questionable (Hendry et al., 2011; Kumar et al., 2012; Shrestha et al., 2014) . By contrast, there was no correlation in binding potential values between the 2 PET probes in conscious animals, possibly reflecting changes in extracellular 5-HT levels due to vigilance state. Indeed, consciousness affects serotonergic neurotransmission in forebrain structures including the hippocampus and hypothalamus (Portas et al., 1998; Park et al., 1999; Shouse et al., 2000; Python et al., 2001) . Given that human PET studies are normally performed without an anesthetic, these results strengthen the rationale for testing both agonist and antagonist PET probes when quantifying 5-HT 1A receptor function.
It is surmised that agonist PET probes such as 18 F-F13714 may be more suitable than 18 F-MPPF for detecting changes in 5-HT 1A receptor function elicited by therapeutic agents such as antidepressants or antipsychotics, many of which act as agonists at this target (see Introduction). Agonist PET probes would also be desirable when assessing the association between 5-HT 1A receptors and behavioral phenotypes. The involvement of the 5-HT 1A receptor in various aspects of cognition, depression, and anxiety has been amply demonstrated (Harder and Ridley, 2000; Gingrich and Hen, 2001; Albert et al., 2014; Stiedl et al., 2015) , but a human database of 5-HT 1A receptor binding by PET with an antagonist probe 11 C-WAY100635 showed high between-subject variability and failed to find any correlations with personality variables (Rabiner et al., 2002) , while several studies reported an association with anxious or aggressive traits in smaller sample sizes (Tauscher et al., 2001; Parsey et al., 2002) .
Some limitations of the present study should be mentioned. Firstly, the data herein are based on a small cohort of marmosets (4 animals). Nevertheless, using the same animals in all conditions allowed us to show clear differences between the 5-HT agonist and antagonist and between conscious and isoflurane conditions. Secondly, there are no data directly showing the selectivity and agonist behavior of 18 F-F13714 binding for 5-HT 1A receptors in the marmoset brain, although the selectivity of F13714 has been documented in vitro (Assié et al., 2006) . Thirdly, the existence of 2 distinct affinity states of 5-HT 1A receptors (high affinity, "functional" state and lower affinity, nonfunctional state ) have not yet been directly demonstrated in vivo and therefore warrants further evaluation (Cumming et al., 2002; Skinbjerg et al., 2012) .
Conclusions
We successfully evaluated 5-HT 1A receptor binding distribution in the marmoset brain using a novel biased agonist PET probe, 18 F-F13714, in comparison with a well-characterized antagonist PET probe, 18 F-MPPF. There were striking differences in the pattern of binding between the 2 PET probes. Whereas 18 F-MPPF showed highest binding in hippocampus and amygdala, 18 F-F13714 showed highest labeling in other regions, including insular and cingulate cortex, thalamus, and raphe nucleus. Marked binding was noted in caudate nucleus and putamen. This distinctive pattern of labeling correlates with results from phMRI brain imaging (Becker et al., 2016) and underpin the remarkably potent antidyskinetic activity of F13714 in rat models of Parkinson's disease (Iderberg et al., 2015) .
The present study also found marked individual-and regionspecific differences under isoflurane-anesthetized vs conscious conditions of PET imaging. Notably, 18 F-F13714 showed a marked difference to 18 F-MPPF with respect to susceptibility to isoflurane, suggesting that the functional state of 5-HT 1A receptors is strongly influenced by anesthesia.
Taken together, these findings highlight the importance of investigating the brain imaging of 5-HT 1A receptors using agonist PET probes, such as 18 F-F13714, and suggest that caution is necessary when interpreting results on serotonin receptor PET imaging when using anesthetized animals. Further studies are required to extend the present observations to human: if biased agonist activity at 5-HT 1A receptors can also be observed under clinical conditions, new opportunities may emerge for treatment of neuropsychiatric and neurological disorders involving serotonergic systems.
